Ensysce Biosciences, Inc. (ENSC) shareholders
Close on Nov 17, 2026Market cap $7.47MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Bob Gene Gower | 1,206,576 | 6.10% | 13D (active) amendment | Aug 7, 2026 |
| Joseph Edelman Joint filing with Perceptive Advisors LLC (5.30%), Perceptive Life Sciences Master Fund, Ltd. (5.30%) | 86,666 | 5.30% | 13G (passive) amendment | Mar 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ENSC | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Jane Street Group, LLC | 208,833 | 1.07% | $60.56K | +195,263 | 0.00% |
| Adage Capital Partners Gp, L.L.C. | 149,711 | 0.77% | $43.42K | – | 0.00% |
| Virtu Financial LLC | 95,391 | 0.49% | $28.00K | +82,078 | 0.00% |
| Perceptive Advisors LLC | 86,666 | 0.45% | $25.13K | – | 0.00% |
| Citadel Advisors LLC | 86,193 | 0.44% | $25.00K | +28,830 | 0.00% |
| XTX Topco Ltd | 77,005 | 0.40% | $22.33K | +52,642 | 0.00% |
| Geode Capital Management, LLC | 62,188 | 0.32% | $18.03K | −11,692 | 0.00% |
| Hrt Financial LP | 54,429 | 0.28% | $15.00K | New | 0.00% |
| Susquehanna International Group, Llp | 34,280 | 0.18% | $9.94K | New | 0.00% |
| Tru Independence Asset Management 2, LLC | 13,000 | 0.07% | $3.77K | – | 0.00% |
| Two Sigma Securities, LLC | 12,953 | 0.07% | $3.76K | New | 0.00% |
| Vanguard Capital Management LLC | 12,854 | 0.07% | $3.73K | – | 0.00% |
| Tower Research Capital LLC (TRC) | 6,094 | 0.03% | $1.77K | – | 0.00% |
| FNY Investment Advisers, LLC | 3,000 | 0.02% | $0 | – | 0.00% |
| Barclays PLC | 1,440 | 0.01% | $418 | New | 0.00% |
| SBI Securities Co., Ltd. | 641 | 0.00% | $186 | +155 | 0.00% |
| BlackRock, Inc. | 65 | 0.00% | $19 | – | 0.00% |
| Clear Street Group Inc. | 1 | 0.00% | $0 | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 18 | 1M | 4.7% | 5 / 5 | 1 / 2 | 0M | 0M |
| Q1 2026 | 15 | 0M | 2.5% | 6 / 5 | 0 / 7 | 0M | 0M |
| Q4 2025 | 17 | 1M | 2.6% | 5 / 7 | 1 / 5 | 0M | 0M |
| Q3 2025 | 17 | 0M | 1.8% | 8 / 3 | 2 / 2 | 0M | 0M |
| Q2 2025 | 11 | 0M | 0.9% | 4 / 2 | 1 / 2 | 0M | 0M |
| Q1 2025 | 9 | 0M | 1.8% | 2 / 4 | 0 / 1 | 0M | 0M |
| Q4 2024 | 8 | 0M | 0.7% | 8 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
3 funds held ENSC in Q1 2026, 38% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of ENSC | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 72,454 | 0.37% | $20.36K | 0.00% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 12,854 | 0.07% | $3.73K | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| James William Morrison | President, Director | – | – | Aug 10, 2026 |
| Bob G. Gower | Director | 916,740 | 4.71% | Aug 18, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Bob G. Gower Director | Aug 7, 2026 | Buy | +400,000 | $0.50 | $200.00K | 916,740 |
| Bob G. Gower Director | Apr 23, 2026 | Buy | +508,614 | $0.48 | $244.13K | 516,740 |
| Bob G. Gower Director | Mar 2, 2023 | Buy | +90,287 | $0.49 | $44.24K | 1,222,682 |
| Bob G. Gower Director | Mar 1, 2023 | Buy | +270,000 | $0.48 | $129.60K | 1,132,395 |
| Bob G. Gower Director | Feb 28, 2023 | Buy | +109,300 | $0.49 | $53.56K | 862,395 |
| Bob G. Gower Director | Dec 9, 2022 | Buy | +357,143 | $1.40 | $500.00K | 753,095 |
| Lynn Kirkpatrick Chief Executive Officer, Director | May 26, 2022 | Buy | +27,000 | $0.53 | $14.31K | 381,851 |
| Lynn Kirkpatrick Chief Executive Officer, Director | May 25, 2022 | Buy | +70,000 | $0.49 | $34.30K | 354,851 |
| Lynn Kirkpatrick Chief Executive Officer, Director | Jun 30, 2021 | Award | +284,851 | – | – | 284,851 |
| Bob G. Gower Director, 10% owner | Jun 30, 2021 | Award | +7,919,026 | – | – | 7,919,026 |
| David Carl Humphrey Chief Financial Officer | Jun 30, 2021 | Award | +50,000 | – | – | 50,000 |
| William H. Chang Director, 10% owner | Jun 30, 2021 | Award | +2,242,189 | – | – | 2,242,189 |
| William H. Chang Director, 10% owner | Jun 30, 2021 | Award | +353,451 | – | – | 353,451 |
| Stanley Morgan 10% owner | Jun 19, 2020 | Sale | −776,290 | – | – | 0 |
| Lane Capital Partners LLC Matthews – | Jan 15, 2018 | Other | −171,832 | – | – | 1,128,370 |
| Eric Carrera Senior Vice President | Jan 15, 2018 | Other | −8,330 | – | – | 54,701 |
| HG Vora Capital Management, LLC 10% owner | Jan 15, 2018 | Other | −375,000 | – | – | 3,462,500 |
| A. Lorne Weil Executive Chairman, Director | Jan 15, 2018 | Other | −40,645 | – | – | 266,900 |
| A. Lorne Weil Executive Chairman, Director | Jan 15, 2018 | Other | −132,158 | – | – | 867,842 |
| George Peng Chief Financial Officer | Jan 15, 2018 | Other | −13,251 | – | – | 87,014 |
| Eric Carrera Senior Vice President | Dec 5, 2017 | Other | −1,465 | – | – | 63,031 |
| Daniel B. Silvers Chief Executive Officer, Director | Dec 5, 2017 | Other | −359,869 | – | – | 1,300,202 |
| HG Vora Capital Management, LLC 10% owner | Dec 5, 2017 | Other | −718,750 | – | – | 2,837,500 |
| A. Lorne Weil Executive Chairman, Director | Dec 5, 2017 | Other | −187,166 | – | – | 307,545 |
| A. Lorne Weil Executive Chairman, Director | Dec 5, 2017 | Other | −169,517 | – | – | 1,000,000 |
| George Peng Chief Financial Officer | Dec 5, 2017 | Other | −733 | – | – | 100,265 |
| HG Vora Capital Management, LLC 10% owner | Dec 1, 2017 | Buy | +1,000,000 | $10.00 | $10.00M | 3,837,500 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Ensysce Biosciences's stock actually held short. Settlement fails (shares not delivered on time) peaked at 111,316 shares on Oct 9, 2026 over the last 90 days.
See a number that looks wrong?